The Food and Drug Administration yesterday issued guidance for the development of a SARS-CoV-2 vaccine, outlining key considerations to satisfy requirements for chemistry, manufacturing and control, nonclinical and clinical data.

The agency said the current goal of vaccine development programs should be “to support traditional FDA approval by conducting studies to directly evaluate the ability of the vaccine to protect humans from SARS-CoV-2 infection and/or disease.”

FDA also authorized the emergency use of the molecular-based LifeHope 2019-nCoV Real-Time RT-PCR Diagnostic Panel. The agency concluded that the qualitative test’s known and potential benefits outweigh the risks during the COVID-19 public health emergency.

Related News Articles

Blog
The American Hospital Association and its Society for Healthcare Strategy and Market Development (SHSMD) July 15 hosted “Addressing COVID-19 Vaccine Hesitancy…
Headline
Read a recap and insights from health care leaders during AHA’s July 15 webinar, “Addressing COVID-19 Vaccine Hesitancy in Your Community,” featuring messaging…
Headline
Three-quarters of the 469 COVID-19 cases associated with summer events and large public gatherings this month in Barnstable County, Mass., were in people fully…
Headline
About 8.9 million children aged 12-17 have received the Pfizer COVID-19 vaccine, the Centers for Disease Control and Prevention reported today. Based on data…
Headline
AHA today joined 27 other organizations that serve the mental, emotional and behavioral health of children in urging Congress to strengthen the pediatric…
Perspective
The COVID-19 Provider Relief Fund has been a lifeline for hospitals, health systems and health care providers, allowing them to continue to put the health and…